The bioethics of iPS cell-based drug discovery.
Clinical pharmacology and therapeutics 2011 May; 89(5): 646-7
The ability to generate human induced pluripotent stem (iPS) cells presents exciting prospects for drug discovery and the development of safer, more effective drugs. Given the enormous potential for iPS cell-based drug development, what ethical issues could possibly cloud this new biomedical horizon?
Permanent LinkFind Full Text at Georgetown University Library
Full Text from Publisher
Showing items related by title, author, creator and subject.
Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges. Hyun, Insoo (2010-06)This paper discusses exceptional circumstances under which patients outside of clinical trials are likely to receive innovative stem cell-based interventions. These circumstances involve: (1) stem cell interventions not ...
Chester, Ronald; Sackstein, Robert (2010)The breakneck speed of scientific developments in embryonic stem (ES) cell technologies is, commensurately, ushering forth new bioethical debate(s) regarding these cells. A framework of bioethical principles is presented ...